Private Asset Management Inc Nektar Therapeutics Transaction History

Private Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 04, 2022	SELL	$4.16 - $13.72 $85,933 - $283,414	-20,657 Closed	0 $0
Q4 2021 Jan 03, 2022	BUY	$10.83 - $18.41 $80,423 - $136,712	7,426 Added 56.13%	20,657 $279,000
Q3 2021 Oct 04, 2021	SELL	$13.07 - $18.84 $351,909 - $507,267	-26,925 Reduced 67.05%	13,231 $238,000
Q2 2021 Jul 06, 2021	SELL	$16.52 - $20.4 $5,782 - $7,139	-350 Reduced 0.86%	40,156 $689,000
Q1 2021 Apr 02, 2021	BUY	$16.56 - $25.46 $52,991 - $81,472	3,200 Added 8.58%	40,506 $810,000

Q4 2020 Jan 05, 2021	BUY	$15.77 - $19.03 $3,942 - $4,757	250 Added 0.67%	37,306 $634,000
Q3 2020 Oct 06, 2020	BUY	$16.59 - $24.79 $13,686 - $20,451	825 Added 2.28%	37,056 $615,000
Q2 2020 Jul 06, 2020	BUY	$16.86 - $23.44 $108,747 - $151,188	6,450 Added 21.66%	36,231 $839,000
Q1 2020 Apr 02, 2020	BUY	$14.47 - $27.96 $147,319 - $284,660	10,181 Added 51.94%	29,781 $532,000
Q4 2019 Jan 03, 2020	BUY	$15.87 - $23.12 $311,052 - $453,152	19,600 New	19,600 $423,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $242M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Private Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Private Asset Management Inc with notifications on news.